1. HBW Insight
  2. >>Digital Technologies

Artificial Intelligence: US FDA Plans Guidances On Algorithm Bias, Product Development

 
• By Derrick Gingery

Cross-center AI strategy features collaboration between drug, biologic, device and combination product staff to ensure regulatory predictability. ‘Assurance labs’ offering independent valuation of models should be available by year-end as part of FDA’s involvement with Coalition for Health AI.

artificial intelligence
• Source: Shutterstock

Identifying and fighting bias in artificial intelligence will be one of many priorities for the US Food and Drug Administration going forward as it enhances its regulatory capacity for the technology.

The FDA’s drug, biologic, and device centers, as well as its Office of Combination Products, will collaborate to ensure regulatory...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of HBW Insight, to focus on AI, business harmonization and long-term growth.

Value Of Consumer Wearables Within The Clinic Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

Bayer Study Shows Potential Of Saliva-Based Biomarker For Healthy Aging

 
• By David Ridley

Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”

Church & Dwight Launching Sugar-Free Vitafusion, Looks To AI As Sweet Spot For All Growth

 
• By Malcolm Spicer

AI prowess “will not be a competitive advantage long-term. It's going to be table stakes. But there are people who are going to get there sooner and they will have an advantage for a while,” says C&D CEO Matthew Farrell. P&G’s investment in AI, meanwhile, produced its “Great Idea Generator proprietary platform.”

More from HBW Insight

Opella Switches Cialis In Norway

 
• By David Ridley

Norway becomes the third European country to approve OTC sales of tadalafil. Cialis reseptfri will “soon be on shelves,” Opella says, with the launched being planned in partnership with Stada Arzneimittel.

Avista Adds To EU Consumer Health Portfolio With PK Benelux Deal

 
• By Tom Gallen

Private equity firm Avista attracted by PK Benelux' "leadership in innovation" in the Dutch vitamins, minerals and supplements market.

Citizen Petition Stirs Loper Bright Decision Into Convincing FDA To Allow 118 Health Claims

 
• By Malcolm Spicer

Alliance of Natural Health launches initiative to change FDA’s use of “significant scientific agreement” standard for allowing health claims with a citizen petition for approval of 118 nutrient-disease health claims.